公开(公告)号：US20240342146A1

公开(公告)日：2024-10-17

申请号：US18753671

申请日：2024-06-25

Applicant: LEIUTIS PHARMACEUTICALS LLP

Inventor： Chandrashekhar KOCHERLAKOTA ,  Nagaraju BANDA

IPC: A61K31/439 ,  A61K31/438 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/573 ,  A61K31/675

CPC classification number: A61K31/439 ,  A61K31/438 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/573 ,  A61K31/675

Abstract: The disclosure relates to chemotherapy treatments and in particular, formulations for antiemetic therapy. Parenteral formulations comprising Palonosetron, NK1 receptor antagonist and a corticosteroid is provided. Also provided is a process of preparing such formulations.

公开(公告)号：US20240058272A1

公开(公告)日：2024-02-22

申请号：US18386863

申请日：2023-11-03

Applicant: LEIUTIS PHARMACEUTICALS LLP

Inventor： Chandrashekhar KOCHERLAKOTA ,  Nagaraju BANDA ,  Santhosh Kumar MANKALA ,  Suresh PACHAIYAPPAN ,  Anji Reddy KESHIREDDY

IPC: A61K9/19 ,  A61K9/00 ,  A61K31/381

CPC classification number: A61K9/19 ,  A61K9/0019 ,  A61K31/381

Abstract: The present invention relates to a parenteral lyophilized formulation of duloxetine or a pharmaceutically acceptable salt thereof. Further, this invention relates to duloxetine dissolved in a suitable solvent system comprising one or more buffers, stabilizers, and other pharmaceutically acceptable excipients and subsequently lyophilized. The invention also describes combination formulation of Duloxetine with other active ingredients.

公开(公告)号：US20230310465A1

公开(公告)日：2023-10-05

申请号：US18021647

申请日：2021-08-18

Applicant: LEIUTIS PHARMACEUTICALS LLP

Inventor： Chandrashekhar KOCHERLAKOTA ,  Nagaraju BANDA ,  Arjun NARALA ,  Naga Udaya Sankar PULLAGURA ,  Srinath AKULA

IPC: A61K31/00 ,  A61K9/127 ,  A61K9/00 ,  A61K9/51 ,  A61K47/44

CPC classification number: A61K31/658 ,  A61K9/1271 ,  A61K9/0053 ,  A61K9/5192 ,  A61K47/44

Abstract: The present invention relates to a formulation comprising a nano lipid carrier system comprising an active ingredient, low phase transition solid lipid, PEGylated lipid, surfactants and cosolvents etc, dispersed in water or aqueous medium. The hydrodynamic diameter of the nanocarrier system in aqueous media is less than about 1000 nm. The present invention formulation can be in the form of a liquid (solution, suspension, dispersion), liquid filled hard gelatin capsule, soft gelatin capsule or a liquid concentrate.

公开(公告)号：US20230190639A1

公开(公告)日：2023-06-22

申请号：US18110202

申请日：2023-02-15

Applicant: LEIUTIS PHARMACEUTICALS LLP

Inventor： Chandrashekhar KOCHERLAKOTA ,  Nagaraju BANDA

IPC: A61K9/00 ,  A61K38/095 ,  A61K9/08 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18

CPC classification number: A61K9/0019 ,  A61K38/095 ,  A61K9/08 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183

Abstract: Provided are novel parenteral formulations of vasopressin, including of vasopressin, stabilizers, solvent and other pharmaceutically acceptable excipients. Also provided are ready to use and/ ready to dilute formulations for parenteral administration. Further provided is a process for preparing formulations of vasopressin for parenteral administration.

公开(公告)号：US20220409544A1

公开(公告)日：2022-12-29

申请号：US17778906

申请日：2020-11-30

Applicant: LEIUTIS PHARMACEUTICALS LLP

Inventor： Chandrashekhar KOCHERLAKOTA ,  Nagaraju BANDA ,  Santhosh Kumar MANKALA ,  Suresh PACHAIYAPPAN ,  Anji Reddy KESHIREDDY

IPC: A61K9/19 ,  A61K31/381 ,  A61K9/00

Abstract: The present invention relates to a parenteral lyophilized formulation of duloxetine or a pharmaceutically acceptable salt thereof. Further, this invention relates to duloxetine dissolved in a suitable solvent system comprising one or more buffers, stabilizers, and other pharmaceutically acceptable excipients and subsequently lyophilized. The invention also describes combination formulation of Duloxetine with other active ingredients.